FAS: the health system is not ready for the risk-sharing drug supply systems

02-06-2017 | 14:50

The national health care system requires drastic changes in terms of clinical recommendations, interactions between medical doctors and pharmaceutical companies as well as creating a uniform system of implementing and objective evaluation of the efficiency of medicinal drugs under a risk-sharing model

“Launching a pilot project on sharing the risks / costs of treatment between pharmaceutical companies and drug ordering parties requires that the health system should have the basis without which drug provision under the risk-sharing system would not generate the expected results. Furthermore, executing the pilot project without taking into consideration FAS comments can restrict competition on the relevant markets and even facilitate breaching the law on public procurement and the antimonopoly law. The first sets of documents that we that we received, unfortunately, fully confirm our concerns”, stated Head of FAS Department for Control over Social Sphere and Trade Timophey Nizhegorodtsev at a special session “Risk-sharing and Value-based models. Regional projects” during Russian Pharmaceutical Forum.

According to Head of the specialized FAS Department, first of all, it is necessary to ensure regulatory and professional support to the institution of clinical recommendations. Second, strengthen the system of medical law, and create working mechanisms based on responsible cooperation between medical doctors and pharmaceutical companies. Third, establish collection and analysis of objective independent information about efficacy and side-effects of medicinal drugs.

“FAS and the Ministry of Health Care are discussing the pilot project. It is not rejected. Nevertheless, if we would like to summarize a particular practice, it should be done under the common standards and efficiency criteria”, clarified Timophey Nizhegorodtsev. “Before moving to the modern drug provision model, we must do lots of routine work. Also it is important that the pilot project is based on the principle of participant responsibility rather than abstract suggestions to its participants”.

 



Site Map

News & Events Press Releases Image Library About FAS Russia What We Do Institutional Memory Mission, Goals, Values Priority Setting Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 OECD meetings 2019 OECD meetings 2020 OECD meetings 2021 FAS Annual Reports OECD-GVH RCC RCC Newsletter Projects ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD 8th UN Conference on Competition 19th session IGE UNCTAD 20th session IGE UNCTAD 21th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents BRICS Competition Law and Policy Centre BRICS Working Groups for the Research of Competition Issues in Socially Important markets Working Group for the Research of Competition Issues in the Pharmaceutical Markets Working Group for the Research of Competition Issues in the Food Value Chains Working Group for the Research of Competition Issues in the Automobile Markets Working Group for the Research of Competition Issues in the Digital Markets BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Document Library Legislation Reports & Analytics Cases & decisions COVID-19 Contacts Give feedback Contact us Links Authorities Worldwide